RESUMEN
Occupational stress and sleep quality are prevalent issues that can impact the physical and mental well-being of adults. An association between occupational stress and sleep quality has been found. However, this association is not entirely the same across different occupational groups. Additionally, variations are present in the research design and instruments employed.This systematic review aims to investigate the association between these two factors and identify gaps and limitations in current research. Articles published between January 1, 2011, and December 31, 2022, were retrieved from the WOS, Scopus, and PubMed databases. Out of 1225 articles, 38 studies met the predetermined inclusion and exclusion criteria and were included in the review. In the study, research designs, samples, instruments, and associations between occupational stress and sleep quality were statistically analyzed.These studies encompassed a diverse range of occupations, including both blue-collar and white-collar workers. Cross-sectional study is the most common research method. The Pittsburgh Sleep Quality Index (PSQI) was the most frequently utilized tool for assessing sleep quality, while there was a wide variety of measurement tools employed to assess occupational stress. The association between occupational stress and sleep quality consistently demonstrated a negative association, although the specific dimensions varied among studies. Moreover, several other factors were identified to have direct or indirect effects on occupational stress and sleep quality. For future research in this field, we propose four recommendations: (1) Consider utilizing objective measures to assess occupational stress and sleep quality. (2) Employ controlled experiments to further validate the causal relationship between occupational stress and sleep quality. (3) Investigate occupational groups that have received less attention. (4) Take into account the potential influence of other factors on occupational stress and sleep quality.
RESUMEN
Purpose: To evaluate the effect of nanosilica and nanoalumina addition in Tech-sil25 maxillofacial silicone before and after exposure to artificial weathering conditions. Materials and Methods: A total of 144 samples were divided into four groups, a control group (n = 12) and three test groups, nanosilica (NS) (n = 36), nanoalumina (NA) (n = 36), and a hybrid nanoparticle (HySA) (n = 60) at different weight percentages (1, 2, and 3 wt. %) was added to Tech-sil25. Samples were exposed to artificial weathering for 100 hours, and subjected to characterizations involving tear strength, shore A hardness, roughness, and tensile strength tests. The data were analyzed using descriptive and inferential statistics using a one-way ANOVA test to determine the level of significance between the groups. Results: After 100 hours of artificial weathering, the one-way ANOVA result shows a highly significant increase in tensile and tear strengths with a minimal increase in hardness and roughness observed in samples containing 2% nanosilica (NS) followed by hybrid nanoparticle (HySA) of 1% nanoalumina (NA) + 1% nanosilica (NS) compared with a control group and other groups. Conclusions: The addition of nanosilica (NS), nanoalumina (NA), and a hybrid nanoparticle (HySA) to the Tech-sil25 maxillofacial silicone improved its mechanical properties. The combination of several filler reinforcements is essential for enhancing silicone's antiaging properties of silicone and maintaining some of its mechanical properties to prolong the service life.
RESUMEN
BACKGROUND: Massive bleeding is one of the commonest salvageable causes of death. The search for an ideal haemostatic agent during massive bleeding is still ongoing. One of the novel haemostatic medications is recombinant activated factor VII (rFVIIa). To date, the usage of rFVIIa during massive haemorrhage among non-haemophiliac patients remains off-label. The aim of this study is to report our experience in using rFVIIa to treat refractory bleeding. METHODS: Medical records of all patients treated with rFVIIa for massive bleeding over an eleven-year period in a single institution were recorded. Treatment indications, 24-h and 30-day mortality, changes in transfusion needs and coagulation profiles after rFVIIa administration were analysed. RESULTS: rFVIIa were administered in 76 patients. Of these, 41 (53.9%) were non-surgical bleeding, followed by 22 patients (28.9%) with trauma, other surgery bleedings in 9 patients (11.8%) and 4 patients (5.4%) with peripartum haemorrhage. Total survival rate was 78.9% within 24 h and 44.7% over 30 days. Among all these patients who had received rFVIIa due to life-threatening haemorrhage, blood and blood product requirements were significantly reduced (P < 0.001), and the coagulation profiles improved significantly (P < 0.05). Two patients with preexisting thromboembolism were given rFVIIa due to intractable bleeding, both survived. No thromboembolic events were reported after the administration of rFVIIa. CONCLUSIONS: rFVIIa significantly improved coagulation parameters and reduced blood product requirements during refractory haemorrhage. Additionally, usage of rFVIIa in trauma and peripartum haemorrhage patients yield better outcomes than other groups of patients. However, the overall mortality rate remained high.
RESUMEN
BACKGROUND: Platelets release more than 30 cytokines to provide primary hemostatic function. In addition, platelets are also known to release antimicrobial peptides upon activation by thrombin. MATERIALS AND METHODS: In this study, comparative analysis of antibacterial activity of activated and non-activated expired platelet concentrate was determined against Gram-positive and Gram-negative bacteria by Kirby-Bauer disk diffusion method. Thrombin was used to prepare activated platelet concentrate. Gram-positive bacteria tested in this study were S.aureus and S.pyogenes and Gram-negative bacteria were E.coli and K.oxytoca. All the bacteria used in this study were sensitive strains from clinical isolates. Activated and non-activated platelet showed no zone of inhibition against S.pyogenes and E.coli. RESULTS: Activated platelet showed antibacterial activity against S.aureus and K.oxytoca with the zone of inhibition of 8.3 ± 0.6 mm and 7.7 ± 0.2 mm, respectively. Zone of inhibition observed in non-activated platelet against S.aureus and K.oxytoca were 7.8 ± 0.4 mm and 7.5 ± 0.3 mm, respectively. CONCLUSIONS: These findings showed that no significant differences in antibacterial activity produced by activated and non-activated platelet. However, zone of inhibition observed in activated and non-activated platelet indicate the presence of antibacterial property in expired platelet.